MedTrace Logo

Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma

NCT05135832 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2021-11-26

No results posted yet for this study

Summary

The purpose of PRORECECA is to test whether adding weekly active patient-reported outcomes to the treatment of patients with metastatic renal cell carcinoma can improve patient-reported physical function.

Conditions

  • Metastatic Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Neoplasm
  • Urologic Cancer
  • Urologic Neoplasms
  • Advanced Renal Cell Carcinoma

Interventions

DEVICE

Electronic patient-reported outcomes regarding symptoms and health-related quality of life

Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles. The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes.

Sponsors & Collaborators

  • Herlev and Gentofte Hospital

    lead OTHER

Principal Investigators

  • Ida Marie L Rasmussen, MD · Herlev and Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135832 on ClinicalTrials.gov